Tempus Lab and Eric Lefkofsky

A company called Tempus Labs is helping physicians to securely obtain their current patients medical history from the point of where the person is being cared for. Recently a 110 million dollar fund raising event was held by Tempus Labs. The money went toward the advancement of the collection and study of the molecular and also clinical data of patients. They have developed a new app which allows doctors access to secure information about their patients.

The Tempus Lab app invention is now easily accessed on Google play or the App Store. It has been tested already with participating doctors across the nation. Physicians who wish to use this app can order it through Tempus Labs. The app can help with looking into different options for different forms of therapy for their patients. They could help the doctor search for clinical trials that their patient could use and qualify for. Tempus Lab would like to be able to achieve a highly accessible platform available to every doctor anywhere they are.

The 110 million dollar fund raising money that would help Tempus Lab also went into growing the operations that it already had and also to go into the study of cardiovascular disease and neurological disorders. The founder of Tempus Lab is Eric Lefkofsky. Currently he is the CEO of the company. The company is making a collection of clinical and molecular data of patients. A computer operating system is being assembled to make the medical data more available to doctors.

The Chicago based business made viewable to the general public a computer operating system called Tempus O. This system was created to cleanse, design and structure clinical data. This allows for more accuracy in medical conclusions. Eric Lefkofsky is associated with Lightbank as a founding partner. In 2006 he created the Lefkofsky Family Floundation. it is a charitable, private foundation. He works with his wife Liz on this. He is a Trustee of Lurie Children’s Hospital of Chicago. He is a professor at the University of Chicago. He is a graduate from the University of Michigan and achieved a Juris Doctor at University of Michigan Law school.

For details: chicago.blueskyinnovation.com/vault/network/lefkofsky-eric/

Eric Lefkofsky is Fighting Cancer with Technology

By the year 2024, more than 18 million people will have cancer. This is 5million people who will be affected as compared to the year 2014. The good news is; things are going to change due to the introduction of Tempus. The main aim of Tempus is focusing on the way cancer is treated. The technology used is current, and every detail is captured for the advantage of most affected cancer patients.

Tempus does not only focus on data. It also goes a mile ahead to focus on the way information about all types of diseases is collected, analyzed and stored. There is a need to have progress notes which have points of interest of patients from the very beginning up to the end. Tempus uses software that can take in natural language and read characters written by a pen. All these advances and technologies are meant to make all-around structured information.

In most cases, human genome sequencing is very expensive. That is why Tempus is also fighting for cheap coats in conducting this process for patients. If that is achieved, the process of treating cancer will do starting from the cellular level. This will prevent much spread of cancer to other parts of the body.

All the above efforts are affected by Eric Lefkofsky and Tempus to accomplish the best outcomes. It is suspected that Eric Lefkofsky is doing this since his wife once had growth, and he felt bad about it. He is out to fight for people who do not have that power and capital to fight for themselves,thus making the society a better place.

Eric Lefkofsky is one of those people were born in 1969. He is a resident of Southfield, Michigan. He is one those who graduated from the University of Michigan with high-class honors. Eric owns the famous Juris Doctor Degree, and he is known to be very successful. Due to his excellent leadership skills, Eric Lefkofsky is known for holding top positions in many organizations in U.S.A. Some of the organizations are institutes like the Art Institute of Chicago and even children’s home.

For details: www.americaninno.com/chicago/eric-lefkofskys-next-move-curing-cancer-at-tempus/

Eric Lefkofksy believes plummeting cost of gene sequencing may lead to cancer cure

As one indication of the breakneck speed of technological development, it’s instructive to look at the incredible reduction in costs of sequencing human genomes. In 2003, the year that the first complete individual human genome was sequenced, the cost to do so was over $100,000,000. Fast forward 14 years, and the cost of sequencing all of an individual’s genes is a relatively paltry $5,000. This is a quantum leap forward in the accessibility of gene sequencing.

But one man, Eric Lefkofsky, believes that not only will gene sequencing play a star role in future cancer research and treatment but that the cost of sequencing individual genomes will continue to plummet, possibly reaching less than $100 in the next decade. At these price levels, essentially every American’s genome could be easily and cheaply sequenced, leading to an explosion in potentially invaluable data that may lead cancer research to the point of finding a virtual cure.

While Lefkofsky is highly optimistic about the development of cheap gene sequencing and the likely impact that it will have on cancer research and treatment, he still urges caution about the expectations of exactly what such a wealth of new information will likely bring. Lefkofsky says that it is still not hugely likely that a universal cure will be found for all types of cancers. They are simply too heterogeneous, with some cancer types being notoriously resistant to treatment.

Instead, Lefkofsky envisions the coming decades bringing better and better treatments for certain subtypes of cancer. For example, cancers that already have solidly performing, well established treatment regimens, such as breast cancer or prostate cancer, may see additional advances that will all but constitute an actual cure. With others, Lefkofksy believes, treatments may advance to the point where having the disease is similar to those in advanced countries living with AIDS. These cancers will still be a serious disease, but with closely following their treatment regimen, those living with these cancers may be able to effectively survive indefinitely, dying from an unrelated cause.

Lefkofsky says that, while these outcomes would not technically amount to a cure, they are exciting enough to motivate an entire generation of research.

for more info: chicagoinno.streetwise.co/2016/07/22/eric-lefkofskys-next-move-curing-cancer-at-tempus/